Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues

Allami,Risala Hussain; Graf,Claudine; Martchenko,Ksenia; Voss,Beatrice; Becker,Marc; Berger,Martin R.; Galle,Peter R.; Theobald,Matthias; Wehler,Thomas C.; Schimanski,Carl C.

doi:10.3892/ol.2016.4139

Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues

Authors:
- Risala Hussain Allami
- Claudine Graf
- Ksenia Martchenko
- Beatrice Voss
- Marc Becker
- Martin R. Berger
- Peter R. Galle
- Matthias Theobald
- Thomas C. Wehler
- Carl C. Schimanski
View Affiliations

Affiliations: First Department of Internal Medicine, Johannes Gutenberg University Hospital of Mainz, D‑55130 Mainz, Germany, Third Department of Internal Medicine, Johannes Gutenberg University Hospital of Mainz, D‑55130 Mainz, Germany, Department of Internal Medicine, Marienhospital Darmstadt, D‑64285 Darmstadt, Germany, Research Group Toxicology and Chemotherapy, German Cancer Research Center, D‑69117 Heidelberg, Germany
Published online on: January 25, 2016 https://doi.org/10.3892/ol.2016.4139
Pages: 1873-1878

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

C-X-C motif chemokine ligand 12 (CXCL12), also termed stromal cell-derived factor-1 (SDF-1) is a small protein 8‑14 kDa in length that is expressed as six isoforms, consisting of SDF‑1α, SDF‑1β, SDF‑1γ, SDF‑1δ, SDF‑1ε and SDF‑1θ. All six isoforms are encoded by the single CXCL12 gene on chromosome 10. This gene regulates leukocyte trafficking and is variably expressed in a number of normal and cancer tissues. The potential role of the novel CXCL12 splice variants as components of the CXCR4 axis in cancer development is not fully understood. The present study aimed to analyze the expression profile of the various SDF‑1 isoforms and SDF‑1 polymorphisms, and the association with the clinicopathological features and overall survival of patients with colorectal cancer (CRC). SDF‑1 polymorphism analysis was performed using restriction fragment length polymorphism (RFLP) analysis in 73 histologically confirmed human CRC tissue samples at various stages of disease. The expression pattern of the SDF‑1 isoforms was analyzed by reverse transcription‑polymerase chain reaction in 40 histologically confirmed human CRC tissue samples obtained at various stages of disease, as well as in matched adjacent normal mucosa samples. The presence of the CXCL12 gene polymorphism rs1801157 demonstrated an association with local progression of the primary tumor, as indicated by the T stage. The frequency of the GG genotype was slightly increased in patients with stage 3 and 4 tumors (78.0%) compared with the incidence of the GA/AA genotype (69.5%; P=0.067). The expression of SDF‑1β was associated with the presence of metastases (P=0.0656) and the expression of SDF‑1γ was significantly associated with tumor size (P=0.0423). The present study is the first to analyze the association between the expression profile of the chemokine CXCL12 splice variants in human CRC tissues and their clinical relevance. The present results reveal that the CXCL12 G801A polymorphism is a low‑penetrance risk factor for the development of CRC, and was associated with the T stage. All six isoforms of SDF‑1 were expressed in CRC tissues. The expression of SDF‑1β was found to be associated with metastases and SDF‑1γ appears to be a possible tumor marker for local tumor progression.

View Figures

View References

1	Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000. View Article : Google Scholar : PubMed/NCBI
2	Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN and Edwards BK: Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 95:1276–1299. 2003. View Article : Google Scholar : PubMed/NCBI
3	Zlotnik A: Chemokines and cancer. Int J Cancer. 119:2026–2029. 2006. View Article : Google Scholar : PubMed/NCBI
4	Premack BA and Schall TJ: Chemokine receptors: gateways to inflammation and infection. Nat Med. 2:1174–1178. 1996. View Article : Google Scholar : PubMed/NCBI
5	Bagglioni M: Chemokines and leukocyte traffic. Nature. 392:565–568. 1998. View Article : Google Scholar : PubMed/NCBI
6	Bleul CC, Schultze JL and Spinger TA: B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state and B cell receptor engagement. J Exp Med. 187:753–762. 1998. View Article : Google Scholar : PubMed/NCBI
7	Schimanski CC, Schwald S, Simiantonaki N, Javasinghe C, et al: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 11:1743–1750. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hao L, Zhang C, Wang L, Luo Y, et al: Recombination of CXCR4, VEGF and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett. 253:34–42. 2007. View Article : Google Scholar : PubMed/NCBI
9	Shanmugam MK, Manu KA, Ong TH, Ramachandran L, Surana R, Bist P, Lim LH, Kumar AP, Hui KM and Sethi G: Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int J Cancer. 129:1552–1563. 2011. View Article : Google Scholar : PubMed/NCBI
10	D'Alterio C, Barbieri A, Portella L, Palma G, Polimeno M, Riccio A, Ieranò C, Franco R, Scognamiglio G, Bryce J, et al: Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol Immunother. 61:1713–1720. 2012. View Article : Google Scholar : PubMed/NCBI
11	Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L and Shim H: Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65:967–971. 2005.PubMed/NCBI
12	Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D and Luker GD: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 64:8604–8612. 2004. View Article : Google Scholar : PubMed/NCBI
13	Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP and Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
14	Sun XS, Wei L, Chen Q and Terek RM: CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer. 9:172010. View Article : Google Scholar : PubMed/NCBI
15	Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA and Strieter RM: Stromal derived factor-I (SDF-I/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer. 5:562006. View Article : Google Scholar : PubMed/NCBI
16	Kollmar O, Rupertus K, Scheuer C, Junker B, et al: Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia. 9:862–870. 2007. View Article : Google Scholar : PubMed/NCBI
17	Mori T, Doi R, Koizumi M, Toyoda E, et al: CXCR4 antagonist inhibits stromal cell-derived factor-1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther. 3:29–37. 2004. View Article : Google Scholar : PubMed/NCBI
18	Yu L, Cecil J, Peng SB, Schrementi J, et al: Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene. 374:174–179. 2006. View Article : Google Scholar : PubMed/NCBI
19	Janowski M: Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 3:243–249. 2009. View Article : Google Scholar : PubMed/NCBI
20	Lombardi L, Tavano F, Morelli F, Latiano TP, Di Sebastiano P and Maiello E: Chemokine receptor CXCR4: Role in gastrointestinal cancer. Crit Rev Oncol Hematol. 88:696–705. 2013. View Article : Google Scholar : PubMed/NCBI
21	Chada S, Ramesh R and Mhashilkar AM: Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther. 5:463–474. 2003.PubMed/NCBI
22	Dimberg J, Hugander A, Löfgren S and Wagsater D: Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med. 19:11–15. 2007.PubMed/NCBI
23	Allami RH: Influence of the chemokine CXCL12 on the progression and the signalling in colorectal cancer. PhD dissertation. Der Johannes Gutenberg-Universität. (ArchiMed, Mainz). 2013.
24	Manetti M, Liakouli V, Fatini C, Cipriani P, Bonino C, Vettori S, Guiducci S, Montecucco C, Abbate R, Valentini G, Matucci-Cerinic M, Giacomelli R and Ibba-Manneschi L: Association between a stromal cell derived factor1 (SDF-1/cxcl12) gene polymorphism and microvascular disease in systemic sclerosis. Ann Rheum Dis. 68:408–411. 2009. View Article : Google Scholar : PubMed/NCBI
25	Liu W, Zhu E, Wang R, Wang L and Liu T: CXCL12 G801A polymorphism is associated with an increased risk of benign salivary gland tumors in the Chinese population. Med Oncol. 29:677–681. 2012. View Article : Google Scholar : PubMed/NCBI
26	Yu L, Cecil J, Peng SB, Schrementi J, Kovacevic S, Paul D, Su EW and Wang J: Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene. 374:174–179. 2006. View Article : Google Scholar : PubMed/NCBI
27	Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J and O'Brien SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS). San Francisco City Cohort (SFCC) Science. 279:389–393. 1998.
28	Razmkhah M, Doroudchi M, Ghayumi SM, Erfani N and Ghaderi A: Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer. 49:311–315. 2005. View Article : Google Scholar : PubMed/NCBI
29	Razmkhah M, Talei AR, Doroudchi M, Khalili-Azad T and Ghaderi A: Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett. 225:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
30	Dommange F, Cartron G, Espanel C, Gallay N, Domenech J, Benboubker L, Ohresser M, Colombat P, Binet C, Watier H and Herault O: GOELAMS Study Group: CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. Faseb J. 20:1913–1915. 2006. View Article : Google Scholar : PubMed/NCBI
31	Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, Tanaka Y and Dahiya R: CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 13:5056–5062. 2007. View Article : Google Scholar : PubMed/NCBI
32	de Oliveira KB, Oda JM, Voltarelli JC, Nasser TF, Ono MA, Fujita TC, Matsuo T and Watanabe MA: CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma and non-Hodgkin's lymphoma. J Clin Lab Anal. 23:387–393. 2009. View Article : Google Scholar : PubMed/NCBI
33	Teng YH, Liu TH, Tseng HC, Chung TT, Yeh CM, Li YC, Ou YH, Lin LY, Tsai HT and Yang SF: Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck. 31:1282–1288. 2009. View Article : Google Scholar : PubMed/NCBI
34	Vairaktaris E, Vylliotis A, Spyridonodou S, Derka S, Vassiliou S, Nkenke E, Yapijakis C, Serefoglou Z, Neukam FW and Patsouris E: A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. Anticancer Res. 28:271–275. 2008.PubMed/NCBI
35	Zhu K, Jiang B, Hu R, Yang Y, Miao M, Li Y and Liu Z: The CXCL12 G801A polymorphism is associated with cancer risk: A meta-analysis. PLoS One. 9:e1089532014. View Article : Google Scholar : PubMed/NCBI
36	Hidalgo-Pascual M, Galan JJ, Chaves-Conde M, Ramírez-Armengol JA, Moreno C, Calvo E, Pelaez P, Crespo C, Ruiz A and Royo JL: Analysis of CXCL12 3′UTR G>A polymorphism in colorectal cancer. Oncol Rep. 18:1583–1587. 2007.PubMed/NCBI
37	Chang SC, Lin PC, Yang SH, Wang HS, Li AF and Lin JK: SDF-1alpha G801A polymorphism predicts lymph node metastasis in stage T3 colorectal cancer. Ann Surg Oncol. 16:2323–2330. 2009. View Article : Google Scholar : PubMed/NCBI
38	Gong H, Tan M, Wang Y, Shen B, Liu Z, Zhang F, Liu Y, Qiu J, Bao E and Fan Y: The CXCL12 G801A polymorphism and cancer risk: evidence from 17 case-control studies. Gene. 509:228–231. 2012. View Article : Google Scholar : PubMed/NCBI
39	Altenburg JD, Broxmeyer HE, Jin Q, Cooper S, Basu S and Alkhatib G: A naturally occurring splice variant of CXCL12/stromal cell-derived factor 1 is a potent human immunodeficiency virus type 1 inhibitor with weak chemotaxis and cell survival activities. J Virol. 81:8140–8148. 2007. View Article : Google Scholar : PubMed/NCBI
40	Janowski M: Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 3:243–249. 2009. View Article : Google Scholar : PubMed/NCBI
41	Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
42	Colobran R, Pujol-Borrell R, Armengol MP and Juan M: The chemokine network II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility. Clin Exp Immunol. 150:1–12. 2007. View Article : Google Scholar : PubMed/NCBI